Treatment-Resistant Depression
If you’ve tried two or more antidepressants without adequate relief, you are not broken. You have treatment-resistant depression, a recognized clinical condition with a growing set of advanced treatment options. Bright Horizons Psychiatry specializes in this population.
Serving Rockville, Bethesda, and Montgomery County
When the standard playbook hasn’t worked.
Most people who start antidepressant treatment improve. About a third do not. Another third see partial improvement but still carry significant symptoms. For these patients, the clinical term is treatment-resistant depression, and it reflects a simple truth. Your biology did not respond to first-line treatment. That is a fact about the medication, not about you.
Treatment-resistant depression has been one of the fastest-evolving areas in psychiatry over the last decade. TMS, Spravato, and more sophisticated medication strategies now give patients who would have been stuck ten years ago real paths to recovery. This is the work Bright Horizons Psychiatry is built around.
What Treatment-Resistant Depression Actually Means
The formal definition requires an inadequate response to at least two trials of antidepressant medication, each at an adequate dose for an adequate duration (usually six to eight weeks). “Inadequate response” means symptoms have not improved by at least 50 percent, or remission has not been achieved.
Several things are worth knowing about this definition.
First, it does not mean your depression is untreatable. It means the medications you’ve tried so far were not the right match. Many patients with treatment-resistant depression respond well to the next step in care, whether that’s medication optimization, TMS, or Spravato.
Second, it is not rare. Estimates suggest that roughly 30 percent of patients with major depressive disorder meet criteria for treatment resistance at some point. You are not alone in this category, and the clinical field has responded with real options.
Third, before concluding that depression is truly treatment-resistant, a careful psychiatric evaluation should rule out contributing factors. Missed diagnosis of bipolar illness, thyroid dysfunction, undiagnosed ADHD, trauma, substance use, or persistent medical illness can all masquerade as treatment failure. A comprehensive evaluation is the first step at Bright Horizons.
TMS for Treatment-Resistant Depression
Transcranial magnetic stimulation is an FDA-cleared treatment that uses targeted magnetic pulses to stimulate the prefrontal cortex, a brain region central to mood regulation. It is non-invasive, drug-free, and performed in our office. Sessions take 20 to 40 minutes and patients drive themselves to and from each appointment.
TMS is indicated specifically for patients who have not responded to at least one antidepressant, which places treatment-resistant depression squarely within its use case. Clinical studies consistently show response rates in the 50 to 60 percent range and remission rates around 30 percent among treatment-resistant patients, numbers that meaningfully outperform additional medication trials at this stage.
TMS for depression cost.
A full course of TMS typically runs $6,000 to $15,000 without insurance, with individual sessions ranging from $300 to $500. However, TMS is covered by most major insurance plans for treatment-resistant depression, including Medicare and most Maryland commercial plans, when medical criteria are met (typically one or more failed medication trials). With insurance, most patients pay between $500 and $3,000 total out of pocket for a full course. We verify coverage before beginning treatment and handle prior authorization on your behalf. These ranges reflect current market averages. Actual cost depends on your specific insurance plan.
ECT vs TMS for depression.
ECT (electroconvulsive therapy) is the oldest established treatment for severe treatment-resistant depression and remains highly effective, particularly for cases involving psychotic features or acute suicidality. However, ECT requires general anesthesia, can produce memory side effects, and is generally reserved for more severe presentations. TMS achieves meaningful outcomes in most treatment-resistant cases with none of those trade-offs, which is why it has become the more commonly recommended first-line advanced treatment. Bright Horizons does not offer ECT. Patients who need ECT are referred to Sheppard Pratt or Johns Hopkins Psychiatry.
Spravato (Esketamine) for Treatment-Resistant Depression
Spravato is an FDA-approved nasal spray treatment for treatment-resistant depression and for depression with suicidal ideation. Unlike traditional antidepressants, which target serotonin and usually take weeks to work, Spravato targets the glutamate system and can produce meaningful relief within days to weeks. It is administered in our REMS-certified office under medical supervision, with monitoring throughout the session.
Spravato is indicated for patients who have tried at least two oral antidepressants without adequate response. For those patients, it represents one of the most significant treatment advances in depression care in decades.
Spravato cost and insurance.
Spravato is covered by most major insurance plans for treatment-resistant depression, typically leaving patients with a copay in the $50 to $400 per session range depending on the plan. Total out-of-pocket cost for the induction phase (eight sessions over four weeks) commonly falls between $300 and $3,200 with good insurance. We verify coverage and handle prior authorization before beginning treatment. These are market averages. Your actual cost depends on your specific plan.
What about ketamine?
IV and intramuscular ketamine are used off-label for depression at many clinics across the country. They are not FDA-approved for depression and are generally not covered by insurance. Typical out-of-pocket costs run $400 to $800 per IV session, with a full initial course of six to eight sessions ranging from $2,400 to $6,400. Because Spravato provides most of the same therapeutic benefit with FDA approval and insurance coverage, we offer Spravato as our primary ketamine-class treatment. For patients specifically seeking IV or IM ketamine, we refer to vetted providers in the region.
How Ketamine Works for Depression
Ketamine (and esketamine) act on the glutamate system rather than on serotonin, which is a fundamentally different mechanism from traditional antidepressants. This explains both why they work on a much faster timeline and why they work for patients whose depression has not responded to serotonin-based medications.
How long does ketamine last for depression?
After a successful initial course, effects typically last several weeks to a few months for most patients, though this varies significantly. Maintenance sessions are commonly scheduled every two to four weeks at first, extending to monthly or longer intervals as stability is achieved.
How long does ketamine work for depression?
The antidepressant effect usually emerges within the first one to three sessions for responders. Unlike SSRIs, which can take four to six weeks to show effect, ketamine-class treatments can produce noticeable improvement within days.
How fast does ketamine work for depression?
For Spravato, most responders notice improvement within the first two weeks. For IV ketamine, some patients feel effects within hours of the first infusion, though this doesn’t mean the effect is durable without follow-up sessions.
Can ketamine make depression worse?
Rarely, but it’s worth addressing. Most patients tolerate ketamine-class treatments well. Some experience dissociative effects during the session that resolve within hours. A small subset of patients may experience worsening mood or anxiety, particularly if there is underlying bipolar illness that was not identified before treatment. This is why careful diagnostic evaluation is essential before starting, and why treatment under medical supervision matters.
What to expect after ketamine treatment for depression.
After Spravato sessions, patients remain in our office for two hours of monitoring. Most feel relatively normal by the end of the monitoring period, though you cannot drive yourself home afterward. Plan for someone to provide transportation on treatment days. Between sessions, most patients continue regular work, family life, and activities without significant interruption.
Medication Strategies for Treatment-Resistant Depression
Before concluding that depression is truly treatment-resistant, medication strategy itself often deserves a second look. A patient may have “failed” two SSRIs without ever trying an SNRI, or may have been on subtherapeutic doses, or may have stopped medication before six weeks of effect could be assessed.
At Bright Horizons, we review the full medication history in detail and consider several strategies when appropriate. Switching to a medication with a different mechanism (for example, moving from an SSRI to an SNRI, bupropion, or mirtazapine). Augmentation, which means adding a second medication to an existing antidepressant to boost response. Common augmenting agents include atypical antipsychotics (aripiprazole, brexpiprazole), lithium, thyroid hormone, and in some cases stimulants. Pharmacogenetic testing to understand how your body metabolizes psychiatric medications, which sometimes explains why previous trials didn’t work.
Medication optimization is often the right first step before moving to TMS or Spravato, particularly if previous trials were incomplete or poorly matched to the presentation.
Treatment-Resistant Bipolar Depression
Treatment-resistant bipolar depression refers to the depressive phase of bipolar illness that has not responded adequately to standard mood stabilizers or bipolar depression medications. It requires a different approach than unipolar treatment-resistant depression because antidepressants alone can destabilize bipolar illness.
Bright Horizons Psychiatry treats Bipolar II disorder and the depressive phase of bipolar illness. For patients with treatment-resistant bipolar depression in this scope, we offer TMS (FDA-cleared for bipolar depression in certain cases), careful mood stabilizer optimization, and Spravato where clinically appropriate.
We do not treat Bipolar I disorder. Patients with Bipolar I or a history of mania are referred to programs equipped for that level of care, including Sheppard Pratt and academic medical centers.
When Is It Time to Consider TMS or Spravato?
You don’t have to wait until you’ve tried ten medications. Evidence-based guidelines now support considering advanced treatments earlier rather than later, particularly when:
Antidepressants have produced little to no response after adequate trials. When side effects from medications make continuing them untenable. When depression has become chronic despite treatment. When suicidal thoughts persist despite medication. When you’ve been stuck in partial response for months or years without full remission.
The most common regret we hear from TMS and Spravato patients is not trying these treatments sooner. If any of the above describes you, an evaluation is the right next step.
Common Questions
Frequently Asked Questions
Ready to Get Started?
The Next Step Is an Evaluation
If you’ve been stuck for a while, the most important thing to know is this. The next treatment is often the one that works. We’ll review what’s been tried, understand why it didn’t work, and build a plan grounded in the evidence for treatment-resistant depression, whether that involves medication optimization, TMS, Spravato, or a combination.
Bright Horizons Psychiatry serves Rockville, Bethesda, and all of Montgomery County, Maryland.